Payment overview · 2025
General Payments
$119.68
6 reported records · 4 companies
Healthcare provider profile · identity verified
William H Chesser, DO
Allopathic & Osteopathic Physicians|Family Medicine · KONAWA, OK · NPI 1508959685
Verified facts
What the public records show
CMS Open Payments records show William H Chesser, DO received $119.68 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 31.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $37.65 | 31.5% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.82 | 28.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.76 | 27.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.45 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $119.68 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $37.65 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $32.76 | 2 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.45 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 51 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
51 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
92 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
78 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 390 | 55 |
| Atorvastatin Calcium | Atorvastatin Calcium | 368 | 95 |
| Gabapentin | Gabapentin | 338 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 305 | 82 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 275 | 32 |
| Omeprazole | Omeprazole | 260 | 70 |
| Lisinopril | Lisinopril | 183 | 51 |
| Pregabalin | Pregabalin | 174 | 29 |
| Losartan Potassium | Losartan Potassium | 172 | 52 |
| Potassium Chloride | Potassium Chloride | 171 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 159 | 42 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 139 | 19 |
| Trazodone Hcl | Trazodone Hcl | 137 | 34 |
| Furosemide | Furosemide | 133 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 58 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 38 |
| Montelukast Sodium | Montelukast Sodium | 118 | 33 |
| Alprazolam | Alprazolam | 114 | 22 |
| Famotidine | Famotidine | 113 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 30 |
| Celecoxib | Celecoxib | 108 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 27 |
| Ozempic | Semaglutide | 103 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 102 | 20 |
| Carvedilol | Carvedilol | 99 | 26 |
| Memantine Hcl | Memantine Hcl | 97 | 22 |
| Trulicity | Dulaglutide | 92 | 13 |
| Farxiga | Dapagliflozin Propanediol | 91 | 23 |
| Meloxicam | Meloxicam | 90 | 25 |
| Metformin Hcl | Metformin Hcl | 90 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 89 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 79 | 26 |
| Eliquis | Apixaban | 78 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 16 |
| Clonazepam | Clonazepam | 74 | 11 |
| Tramadol Hcl | Tramadol Hcl | 74 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 73 | 18 |
| Allopurinol | Allopurinol | 71 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 69 | 22 |
| Sertraline Hcl | Sertraline Hcl | 68 | 14 |
| Simvastatin | Simvastatin | 68 | 17 |
| Ondansetron Odt | Ondansetron | 66 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 63 | 12 |
| Atenolol | Atenolol | 59 | 16 |
| Doxepin Hcl | Doxepin Hcl | 57 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 14 |
| Jardiance | Empagliflozin | 56 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 55 | 16 |
| Mounjaro | Tirzepatide | 51 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 44 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 44 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 29 |
| Prednisone | Prednisone | 39 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | 11 |
| Metformin Hcl Er | Metformin Hcl | 38 | 13 |
| Estradiol | Estradiol | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Topiramate | Topiramate | 37 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 12 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Baclofen | Baclofen | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 17 |
| Ranolazine Er | Ranolazine | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 24 |
| Cefuroxime | Cefuroxime Axetil | 30 | 26 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | suppressed |
| Diazepam | Diazepam | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Torsemide | Torsemide | 26 | suppressed |
| Eszopiclone | Eszopiclone | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Clonidine | Clonidine | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Risperidone | Risperidone | 24 | suppressed |
| Vascepa | Icosapent Ethyl | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Lamotrigine | Lamotrigine | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 17 |
| Finasteride | Finasteride | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | 19 |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Humira Pen | Adalimumab | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Latanoprost | Latanoprost | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Olanzapine | Olanzapine | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Clozapine | Clozapine | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Piroxicam | Piroxicam | 11 | suppressed |
| Qulipta | Atogepant | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
| Wegovy | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $119.68 · 6 records | PFIZER INC. | ABRYSVO, COMIRNATY, MOUNJARO, PREVNAR 20, Saxenda, UBRELVY, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error